DeCure's autonomous Cancer AI scientist is researching a drug-repurposing hypothesis for head and neck malignant neoplasia — screening already-approved drugs against its 44-gene Open Targets disease module to publish open-access research. Research is fast; the path to publication is funded in milestone stages.
Disease moduleHead and neck malignant neoplasia maps to a 44-gene Open Targets module — the target space DeCure's AI scientist screens approved drugs against.
DeCure.ai methodSignature reversal (LINCS) plus network proximity (STRING) rank already-approved drugs likely to perturb this module — the same engine that produces DeCure.ai's repurposing hypotheses.
Repurposing thesisScreening approved medicines against this disease module, then publishing the evidence for the strongest candidate. Known pharmacology and human exposure data make the first question sharper — they do not establish safety or efficacy in a new indication.
Research record
01
ResearchComing soon
Candidate research + dossier — target rationale, drug-repurposing thesis and evidence pack.proof: Published dossier + on-chain hash
02
ValidationComing soon
In-vitro biological validation at a contract research org (CRO).proof: CRO contract + in-vitro report
03
Peer review & paperComing soon
Peer-reviewed paper published open-access (preprint + journal).proof: DOI + open-access link + on-chain hash
Current lead
No approved-drug candidate for head and neck malignant neoplasia is corroborated in the literature DeepSearch retrieved. Some conditions are managed with non-pharmacological care — a device, surgery or physical therapy — rather than a medicine; that may be the case here, or the literature we found may simply be too sparse yet to support a drug-repurposing angle.
Molecular view
alcohol dehydrogenase 1B (class I), beta polypeptide (ADH1B) — ADH1B is one of the genes genetically linked to this disease in Open Targets — shown as context, not as a drug target we're pursuing: no approved-drug candidate for this disease is yet corroborated in the literature we found.
Loading structure…
helix sheet naddrag to rotate · scroll to zoom
RCSB Protein Data Bank · entry 1U3U · 1.6 Å · ligand NICOTINAMIDE-ADENINE-DINUCLEOTIDE (NAD). Experimental structure, not a prediction.
What the evidence adds up to
Head and neck cancers are molecularly and genetically heterogeneous despite sharing histological and etiological features, and the psychosocial impact of the disease is described as extremely devastating. One person dies every hour of every day from these cancers. A 2023 review states that traditional treatments such as surgery, radiation, and chemotherapy have limited efficacy and often produce significant side effects. Drug repositioning — using existing drugs approved for other indications — is presented as a strategy that could accelerate development by leveraging known safety and pharmacokinetic data, but the review does not name any specific repurposed drug or report any clinical outcomes.
A 1988 retrospective study of 52 previously untreated patients with advanced head and neck cancer (stages III and IV) treated between 1978 and 1985 used induction chemotherapy followed by radiation as definitive treatment. The group included 38 males and 14 females, median age 62 years, with squamous cell carcinoma at sites including oral cavity (14), oropharynx (18), hypopharynx (8), larynx (9), and unknown primary (3). Seventy-three percent had stage IV cancer. The abstract reports no survival or response rates, and no comparison to surgery is given; the paper is described only as a report of efforts to achieve results comparable or better than surgery.
No concrete numbers for survival, response rates, or sample sizes from any drug-repurposing trial are provided in these abstracts. The 2023 review mentions promising drug candidates but does not name them or give any efficacy data. What is still missing is any completed, randomised trial of a repurposed drug for head and neck cancer that reports survival or response outcomes, as well as patient stratification by the molecular subtypes that the 2016 review emphasises. Funding for such trials and clear identification of which existing drugs might work in which genetic subgroups remain absent.
Evidence
Retrieved by DeepSearch across 234,678,978 indexed works and resolved on OpenAlex — ranked by citations, including the results that did not work.
Journal of Head & Neck Physicians and Surgeons · 2016 · 8 citations · open access
Molecular biology of head and neck cancers
AbstractHead and Neck cancers constitute a real challenge for oncologists across the globe, with one person dying every hour of every day. It can distort and disfigure the face, strip away the voice and rob one of his basic abilities to eat, drink and swallow. The psychosocial impact can be extremely devastating. From previously being considered a homogenous entity, it is now a well recognized fact that Head and Neck cancer is rightly called “Head and neck cancers” in view of their genetic and molecular heterogeneity despite sharing histological and etiological homogeneity. The present review discusses recent insights as well as established principles of the molecular biology of Head and Neck Cancers.
Archives of Otolaryngology - Head and Neck Surgery · 1988 · 0 citations
Methods of Treating Advanced Head and Neck Cancer
AbstractClinicians continue to look for methods of treating advanced head and neck cancer through the use of drugs and/or irradiation that will give comparable or better results than those obtained with surgery. Kadish et al reported on the efforts of St Vincent's Hospital in Worcester, Mass, to achieve this goal. A series of 52 previously untreated patients with advanced head and neck cancer (stages III and IV) seen between 1978 and 1985 and treated with induction (neoadjuvant) chemotherapy followed by radiation therapy as definitive treatment was retrospectively reviewed and reported at the Second International Head and Neck Oncology Research Conference. The study group included 38 males and 14 females with a median age of 62 years. Anatomic sites included oral cavity (14), oropharynx (18), hypopharynx (8), larynx (9), and unknown primary (3). All patients had squamous cell carcinoma. Seventy-three percent of the group had stage IV cancer. Patients were either
Korean Journal of Otorhinolaryngology - Head and Neck Surgery · 2023 · 0 citations · open access
Drug Repositioning for Treatment of Head and Neck Cancers
AbstractHead and neck cancer (HNC) is a complex disease that poses significant therapeutic challenges. Traditional treatment options such as surgery, radiation, and chemotherapy have limited efficacy and often result in significant side effects. In recent years, drug repositioning has emerged as a promising strategy to identify new therapeutic options for HNC. Drug repositioning involves repurposing existing drugs, already approved for other indications, for the treatment of HNC. This approach takes advantage of existing knowledge about drug safety and efficacy, reducing the time and cost needed to develop new drugs. By leveraging the known safety profiles, pharmacokinetic, and pharmacodynamic properties of these drugs, drug repositioning can accelerate the drug development process and reduce costs. In this review, the current status of drug repositioning efforts for HNC and the challenges and opportunities associated with this approach are discussed. We also highlight some of the most promising drug candidates that have emerged from recent studies and clinical trials. Overall, drug repositioning has the potential to significantly improve the treatment landscape for HNC and offer new hope for patients with this challenging disease.
AbstractThis fairly slim book (284 pages of text) is one of 37 volumes in the series “Cancer Treatment and Research”, which have been published in the last 6 years. The Series Editor, William L. McGuire, states in the Foreword that the aims of this series are to produce “authoritative articles on the diagnosis and management of particular malignancies”, head and neck cancer in this instance. It is intended that eminent authorities edit each volume on an annual or bi-annual basis, thereby keeping abreast of advances in each field. This volume is divided into four sections: Advances in Surgical Therapy, Advances in Radiation Therapy/Radiology, Advances in Chemotherapy/Biologic Modifiers, and finally Management problems.
Disease module: DeepOracle (Open Targets). Structures: RDKit from PubChem SMILES. Literature: retrieved by DeepSearch across 234,678,978 indexed works (targeted per-candidate search), resolved on OpenAlex.
DeCure is a research and publication project, not medical advice and not a treatment. "DeCure for X" describes a research goal, not a claim that a cure exists. Backing a cure is a contribution to fund the research — it is not an investment, and confers no yield, royalty, equity or IP ownership. Papers are published open-access by the DeCure.ai DAO.
